卡瑞利珠单克隆抗体联合阿帕替尼治疗中晚期肝细胞癌患者疗效及预后分析*

doi:10.3969/j.issn.1672-5069.2024.01.025

Abstract

Abstract: Objective This clinical trial was conducted to investigate the efficacy of camrelizumab and apatinib combination in the treatment of patients with advanced hepatocellular carcinoma (HCC). Methods A total of 117 patients with advanced HCC were admitted to the first affiliated Hospital of Xinjiang Medical University between June 2019 and October 2021, and 65 patients were treated with camrelizumab and apatinib combination, and 52 patients were treated by apatinib alone. All patients were followed-up for one year. The therapeutic efficacy was evaluated according to mRECIST, the progression-free survival (PFS) and its influencing factors were analyzed by Kaplan-Meier method, and the prognostic factors of PFS were analyzed by multivariate COX regression. Results The objective remission rate (ORR) and the disease control rate (DCR) in patients with combination treatment were 44.7% and 66.2%, both significantly greater than 15.4% and 42.3% in the apatinib-treated patients (P<0.05); at the end of three-month treatment, the blood platelet count in patients with combination treatment was 81.0(51.5, 145.5)×10⁹/L, much lower than [107.0(69.5, 191.0)×10⁹/L P<0.05] in patients with apatinib treatment alone; the PFS in patients with combination treatment was 10.6 (95%CI:9.986-11.16) months, significantly longer than 7.9 (95%CI:6.84-8.944) months in the apatinib-treated group (Log-rank=12.807,P<0.05); the performance status (PS), Child-Pugh score, CNLC stage, liver cirrhosis, portal vein tumor thrombus and transarterial chemoembolization (TACE) were the prognostic factors impacting PFS, and the multivariate COX regression analysis showed that the Child-Pugh grade B (HR=2.379,P=0.021) and portal vein tumor thrombus (HR=3.481,P=0.003) were the independent risk factors for PFS, while the TACE (HR=0.528, P=0.034) was an independent protective factor for PFS in patients with advanced HCC. Conclusion The combination of camrelizumab and apatinib in treating patients with advanced HCC could effectively improve the clinical efficacy, with an obvious prolonged survival period. For patients with high tumor load, the auxiliary TACE might help raise better clinical benefits.

Key words: Hepatocellular carcinoma, Camrelizumab, Apatinib, Therapy, Advanced

Ye Mengmeng, Deng Zerun, Zhang Tao. Improved benefit of camrelizumab and apatinib combination in the treatment of patients with advanced hepatocellular carcinoma[J]. Journal of Practical Hepatology, 2024, 27(1): 96-100.

References

[1] 中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2022年版). 肿瘤防治研究, 2022, 49(3): 251-276.
[2] Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol, 2019, 16(10): 589-604.
[3] Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol, 2009, 10(1): 25-34.
[4] Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008, 359(4): 378-390.
[5] Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol, 2018, 19(7): 940-952.
[6] El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet, 2017, 389(10088): 2492-2502.
[7] Kudo M. Scientific rationale for combined immunotherapy with PD-1/PD-L1 antibodies and VEGF inhibitors in advanced hepatocellular carcinoma. Cancers (Basel), 2020, 12(5): 1089.
[8] Simcock R, Wright J. Beyond performance status. Clin Oncol (R Coll Radiol), 2020, 32(9): 553-561.
[9] Lencioni R, Llovet JM. Modified recist (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis, 2010, 30(1): 52-60.
[10] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin, 2020, 70(1): 7-30.
[11] Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health, 2018, 6(5): e555-e567.
[12] Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol, 2022, 76(4): 862-873.
[13] Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol, 2021, 22(7): 977-990.
[14] Xu J, Shen J, Gu S, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase II trial. Clin Cancer Res, 2021, 27(4): 1003-1011.
[15] Qin S, Chan LS, Gu S, et al. Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): a randomized, phase III trial. Ann Oncol, 2022, 33(7): S1401-S1402.
[16] 中国临床肿瘤学会(CSCO). 原发性肝癌诊疗指南(2022年). 北京: 人民出版社, 2022: 88-89.
[17] Bai DS, Zhang C, Chen P, et al. The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Sci Rep, 2017, 7(1): 12870.
[18] Zheng Y, Zhu M, Li M. Effects of alpha-fetoprotein on the occurrence and progression of hepatocellular carcinoma. J Cancer Res Clin Oncol, 2020, 146(10): 2439-2446.
[19] Xu LX, He MH, Dai ZH, et al. Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma. Ann Oncol, 2019, 30(6): 990-997.
[20] Nie M, Liu Y, Li XX, et al. PD-1/PD-L pathway potentially involved in ITP immunopathogenesis. Thromb Haemost, 2019, 119(5): 758-765.

Improved benefit of camrelizumab and apatinib combination in the treatment of patients with advanced hepatocellular carcinoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Jin Keke, Ding Huiguo. Risk and anticoagulation management of cirrhotic patients with portal vein thrombosis [J]. Journal of Practical Hepatology, 2024, 27(1): 3-6.
[2]	Zhang Ming. Portal vein thrombosis in cirrhotic patients: the states of the art [J]. Journal of Practical Hepatology, 2024, 27(1): 11-15.
[3]	Tang Zhiquan, Yang Ting, Li Kailing. Impact of hyperuricemia on virological response to sofosbuvir/daratavir therapy in patients with chronic hepatitis C [J]. Journal of Practical Hepatology, 2024, 27(1): 28-31.
[4]	Wang Yan, Han Jun, Yang Meirong. Twenty-four month follow-up for patients with chronic hepatitis C after sustained virological response to different DAAs treatment regimen [J]. Journal of Practical Hepatology, 2024, 27(1): 32-35.
[5]	Huang Jiejie, Zheng Qian, Lyu Rui, et al. Efficacy of liraglutide and atorvastatin calcium combination in treating patients with nonalcoholic fatty liver diseases complicated with abnormal glucolipid metabolism [J]. Journal of Practical Hepatology, 2024, 27(1): 36-39.
[6]	Wang Wenchuan, Liang Kuopeng, He Ruiling, et al. Prevalence of non-alcoholic fatty liver diseases in patients with type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2024, 27(1): 40-43.
[7]	Yan Yuting, Jia Gui, Meng Qin, et al. Thyroid functions and their impact on response to standardized therapy in patients with autoimmune hepatitis and primary biliary cholangitis [J]. Journal of Practical Hepatology, 2024, 27(1): 52-55.
[8]	Li Xinli, Qin Changjiang, Yin Fangfang. Efficacy of terlipressin treatment after endoscopic variceal ligation in the treatment of patients with liver cirrhosis complicated by esophageal and gastric variceal bleeding [J]. Journal of Practical Hepatology, 2024, 27(1): 76-79.
[9]	Fan Ming, Yang Long, Jin Liang, et al. Different hepatic inflow occlusion techniques during laparoscopic hepatectomy in treatment of patients with primary liver cancer [J]. Journal of Practical Hepatology, 2024, 27(1): 101-104.
[10]	Bao Tianshu, Du Yemu, Yao Shanwen, et al. Short-term efficacy of three-dimensional conformal radiotherapy in patients with primary liver cancer [J]. Journal of Practical Hepatology, 2024, 27(1): 105-108.
[11]	Zheng Hao, Wang Hongjian, Liu Jingjing. Clinical features of Klebsiella Pneumonia-induced bacterial liver abscess [J]. Journal of Practical Hepatology, 2024, 27(1): 121-124.
[12]	Jia Yongli, Wang Pengchuan, Guo Wei, et al. Efficacy of ultrasound-guided injection of absolute ethanol or lauromacrogol in treating patients with hepatic cysts [J]. Journal of Practical Hepatology, 2024, 27(1): 125-128.
[13]	Hu Guangming, Zhou Tao, Xiao Jie, et al. Combination of laparoscopic cholecystectomy and laparoscopic common bile duct exploration in treatment of patients with gallbladder and common bile duct stones: Is the nasobiliary drainage superior to T-tube drainage? [J]. Journal of Practical Hepatology, 2024, 27(1): 129-132.
[14]	Wang Dongjun, Zhang Chunyan, Chao Xiangsong, et al. Evaluation of surgical risk in patients with liver cirrhosis and acute cholecystitis by cholecystitis severity grading and MELD scores [J]. Journal of Practical Hepatology, 2024, 27(1): 133-136.
[15]	Xu Yuan, Zhang Bo. Application of laparoscopic cholecystectomy under guidance of indocyanine greennear infrared fluorescence in treatment of patients with gallstones [J]. Journal of Practical Hepatology, 2024, 27(1): 141-144.